TPL-2 MEK kinase is not targeted by mutation in diffuse large B cell lymphoma and myeloid leukemia

Leukemia Research

Volumn 31, Issue 11, 2007, Pages 1604-1607

  Shirali, Sima ^a   Hamoudi, Rifat A ^a   Bench, Anthony ^b   Scott, Mike ^b   Ley, Steven C ^c   Du, Ming Qing ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2;

B CELL LYMPHOMA; DNA SEQUENCE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE MUTATION; HUMAN; LARGE CELL LYMPHOMA; LETTER; MYELOID LEUKEMIA; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; TPL 2 GENE;

BASE SEQUENCE; DNA PRIMERS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION;

EID: 35548973924     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.12.020     Document Type: Letter

References (11)

1. Beeram M., Patnaik A., and Rowinsky E.K. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 23 (2005) 6771-6790
2. Symons A., Beinke S., and Ley S.C. MAP kinase kinase kinases and innate immunity. Trends Immunol 27 (2006) 40-48
3. Miyoshi J., Higashi T., Mukai H., Ohuchi T., and Kakunaga T. Structure and transforming potential of the human cot oncogene encoding a putative protein kinase. Mol Cell Biol 11 (1991) 4088-4096
4. Chan A.M., Chedid M., McGovern E.S., Popescu N.C., Miki T., and Aaronson S.A. Expression cDNA cloning of a serine kinase transforming gene. Oncogene 8 (1993) 1329-1333
5. Patriotis C., Makris A., Bear S.E., and Tsichlis P.N. Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T- cell activation. Proc Natl Acad Sci U S A 90 (1993) 2251-2255
6. Ceci J.D., Patriotis C.P., Tsatsanis C., Makris A.M., Kovatch R., Swing D.A., et al. Tpl-2 is an oncogenic kinase that is activated by carboxy-terminal truncation. Genes Dev 11 (1997) 688-700
7. Sourvinos G., Tsatsanis C., and Spandidos D.A. Overexpression of the Tpl-2/Cot oncogene in human breast cancer. Oncogene 18 (1999) 4968-4973
8. Christoforidou A.V., Papadaki H.A., Margioris A.N., Eliopoulos G.D., and Tsatsanis C. Expression of the Tpl2/Cot oncogene in human T-cell neoplasias. Mol Cancer 3 (2004) 34
9. Eliopoulos A.G., Davies C., Blake S.S., Murray P., Najafipour S., Tsichlis P.N., et al. The oncogenic protein kinase Tpl-2/Cot contributes to Epstein-Barr virus-encoded latent infection membrane protein 1-induced NF-kappaB signaling downstream of TRAF2. J Virol 76 (2002) 4567-4579
10. Clark A.M., Reynolds S.H., Anderson M., and Wiest J.S. Mutational activation of the MAP3K8 protooncogene in lung cancer. Genes Chromosomes Cancer 41 (2004) 99-108
11. Edwards S.M., Kote-Jarai Z., Hamoudi R., and Eeles R.A. An improved high throughput heteroduplex mutation detection system for screening BRCA2 mutations-fluorescent mutation detection (F-MD). Hum Mutat 17 (2001) 220-232